Home Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for... Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - August 25, 2026 140 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENZAMET (ANZUP 1304) study Source RELATED ARTICLESMORE FROM AUTHOR Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness: Research from the 2023 ASCO Quality Care Symposium FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation Engaging People with Low-Grade Glioma in Cancer Research MOST POPULAR “If there is an under-representation of ethnic minority communities, there will... September 18, 2020 EMA Recommends Extension of Indications for Cabozantinib July 10, 2025 Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health October 27, 2023 Cancer in My Community: Reducing Tobacco Use in Tunisia December 8, 2022 Load more HOT NEWS No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer From smart knives to virtual reality tumours: five innovations in understanding... NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials
